| DESCRIPTION | - LEVEY ASBOSCH JPLEWIS JB et al., "A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group", Ann Intern Med, (19990316), vol. 130, no. 6, pages 461 - 70, XP009189890 | - |
| DESCRIPTION | - N Engl J Med, (20010000), vol. 345, pages 1667 - 1675 | - |
| OPPOSITION | - Anonymous, "Diovan (Valsartan) Tablets. FDA label. Reference ID: 3199353", Novartis Pharmaceuticals Corp., (20121001), pages 1 - 20, XP055780468 | - |
| OPPOSITION | - Anonymous, "Diovan (valsartan) Tablets - Statistical Review and Evaluation", FDA, (20020101), FDA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-283S001_Diovan_statr.pdf, XP093195179 | - |
| OPPOSITION | - Anonymous, "EFFECT OF ENALAPRIL ON MORTALITY AND THE DEVELOPMENT OF HEART FAILURE IN ASYMPTOMATIC PATIENTS WITH REDUCED LEFT VENTRICULAR EJECTION ", The New England Journal of Medicine, (19920903), vol. 327, no. 10, pages 685 - 691, XP093195174 | - |
| OPPOSITION | - Anonymous, "Entresto - Summary of Product Characteristics", (20240404), XP093148148 | - |
| OPPOSITION | - Anonymous, "ICH Topic E 10 Choice of Control Group in Clinical Trials ", European Medicines Agency, pages 1 - 30, URL: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-10-choice-control-group-clinical-trials-step-5_en.pdf, XP093263267 | - |
| OPPOSITION | - Anonymous, "Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696", tctmd.com, tctmd.com, URL: https://www.tctmd.com/news/novartis-showcase-heart-failure-leadership-esc-congress-2014-results-new-first-its-type, XP093299265 | - |
| OPPOSITION | - Anonymous, "PARADIGM-HF Study Halted Early For Large Benefit", American College of Cardiology, American College of Cardiology, URL: https://www.acc.org/Latest-in-Cardiology/Articles/2014/03/31/19/13/PARADIGM-HF-Study-Halted-Early, XP093299261 | - |
| OPPOSITION | - Anonymous, "PARADIGM-HF trial stopped early for benefit", European Society of Cardiology The ESC ESC Press Office Press releases, (20040516), pages 1 - 4, European Society of Cardiology The ESC ESC Press Office Press releases, URL: https://www.escardio.org/The-ESC/Press-Office/Press-releases/PARADIGM-HF-trial-stopped-early-for-benefit, (20220117), XP055879620 | - |
| OPPOSITION | - Anonymous, "Systolic Heart Failure", Cleveland Clinic, (20220614), XP093299305 | - |
| OPPOSITION | - Anonymous, "Therapie der Herzinsuffizienz", Mutschler Arzneimittelwirkungen Pharmakologie - Klinische Pharmakologie - Toxikologie, (20200101), pages 435 - 435, ISBN 978-3-8047-3663-4, XP093148941 | - |
| OPPOSITION | - Anonymous, "This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure (PARADIGM-HF)", ClinicalTrials.gov ID NCT01035255, ClinicalTrials.gov ID NCT01035255, URL: https://www.clinicaltrials.gov/study/NCT01035255?term=NCT01035255&rank=1&tab=history&a=14%2523version-content-panel, XP093197558 | - |
| OPPOSITION | - Crunkhorn Sarah, "Dual-acting combination meets heart failure end point", Nature Reviews, (20121001), vol. 11, page 740, XP055810895 | - |
| OPPOSITION | - Cuculi Florim, Erne Paul, "Combined neutral endopeptidase inhibitors", Expert Opinion on Investigational Drugs, (20110215), vol. 20, no. 4, pages 457 - 463, XP055780113 | - |
| OPPOSITION | - D24 - U.S. National Institute of Health database of clinical studies, automatically saved on the date of December 18, 2012, referring to "PARADIGM HF" | - |
| OPPOSITION | - D26a - Communication from the Board in T 1098/22 dated October 15, 2015 | - |
| OPPOSITION | - D27 - Excerpt (section 3) of the patentee's reply to notices of opposition relating to the parent patent dated January 24, 2025 | - |
| OPPOSITION | - D32 - Excerpt from the Center for Drug Evaluation and Research approval package for Diovan® including Memorandum by Robert Temple | - |
| OPPOSITION | - D33 - Response to the communication under Article 94(3) EPC dated 3 October 2013 | - |
| OPPOSITION | - D34 - T0239/16 | - |
| OPPOSITION | - D35 - T2506/12 | - |
| OPPOSITION | - D36 - T0096/20 | - |
| OPPOSITION | - D42 - Australian Medicines Handbook 1998, pages 6-18 to 6-57 | - |
| OPPOSITION | - D48 - Statement by the Examining Division of September 12, 2025, retrieved from epoline (“23202190-2024-09-12-TIPAINFO Information about non-relevance of third-party observations”) | - |
| OPPOSITION | - D51 - Decision of the Opposition Division in the grandparent case | - |
| OPPOSITION | - D58 - medscape.com, Chronic HF Trial of Novartis Agent Halted Early for Benefit, April 2, 2014 | - |
| OPPOSITION | - D59 - healio.com, PARADIGM-HF stopped early after primary endpoint met, April 3, 2014 | - |
| OPPOSITION | - D60 - escardio.org, PARADIGM-HF trial stopped early for benefit, May 16, 2014 | - |
| OPPOSITION | - D61 - medscape.com, PARADIGM HF Teases With Visions of New Paradigm for Treating Chronic Heart Failure, May 20, 2014 | - |
| OPPOSITION | - Doust Jenny, Lehman Richard, Glasziou Paul, "The role of BNP testing in heart failure", AMERICAN FAMILY PHYSICIAN, American Academy of Family Physicians, US, US , (20060101), vol. 74, no. 11, ISSN 0002-838X, pages 1893 - 1898, XP093195089 | - |
| OPPOSITION | - Ema, "Entresto®", ANNEX I Summary of Product Characteristics, (20151119), pages 1 - 18, ANNEX I Summary of Product Characteristics, URL: https://www.ema.europa.eu/, XP093197877 | - |
| OPPOSITION | - Emea, "ICH Topic E 9 Statistical Principles for Clinical Trials Step 5 NOTE FOR GUIDANCE ON STATISTICAL PRINCIPLES FOR CLINICAL TRIALS", EMEA CPMP/ICH/363/96, (19980901), pages 1 - 37, EMEA CPMP/ICH/363/96, XP093192237 | - |
| OPPOSITION | - Forth W., D. Henschler Und W. Rummel, "Allgemeine und spezielle Pharmakologie und Toxikologie", Allgemeine und spezielle Pharmakologie und Toxikologie, 9., völlig überarbeitete Auflage, München, Jena, URBAN & FISCHER, Elsevier, (20050101), pages 92 - 422-433, XP093040425 | - |
| OPPOSITION | - Jordaan P, Albrecht D, Feng A, Chandra P, Koboleva Z, Averkov O, Alexandriya L, Meray I, Moiseev V, , "Changes in RAAS (renin angiotensin aldosterone system) biomarkers in stable chronic heart failure (HF) patients following short-term angiotensin receptor neprilysin inhibitor (ARNI) treatment", SA Heart Congress 2011, (20110101), vol. 8, no. 4, page 236, XP093194300 | - |
| OPPOSITION | - Julian Segura Jorge Salazar Luis M Ruilope, "Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition", CURRENT OPINION IN INVESTIGATIONAL DRUGS., CURRENT DRUGS, LONDON., GB, GB , (20130701), vol. 22, no. 7, ISSN 0967-8298, pages 915 - 925, XP009174158 | - |
| OPPOSITION | - Kobalava Zhanna, Pavlikova Elena, Averkov Oleg, Moiseev Valentin, Albrecht Diego, Feng Aimen, Chandra Priyamvada, Jordaan Pierre J, "Abstract 19378: First Experience with Concomitant AT1 and Neprilysin (NEP 24.11) Inhibition with LCZ696 in Patients with Chronic Heart Failure", Circulation, (20180323), vol. 122, no. Suppl. 21, XP093147856 | - |
| OPPOSITION | - Luchner Andreas, Et Al, "Bedeutung der Herzinsuffizienzmarker BNP und NT-proBNP für die Klinik", Deutsches Arzteblatt, (20031212), vol. 100, no. 50, pages A3314 - A3321, XP055788524 | - |
| OPPOSITION | - Maggioni, A.P. ; Anand, I. ; Gottlieb, S.O. ; Latini, R. ; Tognoni, G. ; Cohn, J.N. ; the Val-HeFT Investigators, "Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20021016), vol. 40, no. 8, ISSN 0735-1097, pages 1414 - 1421, XP027372571 | - |
| OPPOSITION | - Monika Mutschler, Ernst Geisslinger, Gerd Kroemer, Heyo K. Schäfer-Korting, "14.2.3.3 Aliskiren", Monika Mutschler, Ernst Geisslinger, Gerd Kroemer, Heyo K. Schäfer-Korting, Mutschler, Geisslinger, Kroemer, Menzel, Ruth, Mutschler - Arzneimittelwirkungen, Stuttgart , Wissenschaftliche Verlagsgesellschaft , (20130101), pages 510 - 513, ISBN 978-3-8047-2898-1, XP009562480 | - |
| OPPOSITION | - Monika Mutschler, Ernst Geisslinger, Gerd Kroemer, Heyo K. Schäfer-Korting, "14.3.3.1 Pathophysiologische Grundlagen", Monika Mutschler, Ernst Geisslinger, Gerd Kroemer, Heyo K. Schäfer-Korting, Mutschler, Geisslinger, Kroemer, Menzel, Ruth, Mutschler - Arzneimittelwirkungen, Stuttgart , Wissenschaftliche Verlagsgesellschaft , (20130101), pages 541 - 544, ISBN 978-3-8047-2898-1, XP009562479 | - |
| OPPOSITION | - Pfeffer Marc A, Et Al, "Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both", The New England Journal of Medicine, Massachusetts Medical Society, (20031113), vol. 349, no. 20, pages 1893 - 1906, XP055791018 | - |
| OPPOSITION | - Philip Rowe, "8 The two-sample t-test (3). False negatives, power and necessary sample sizes", Essential Statistics for the Pharmaceutical Sciences, Wiley, (20070101), pages 89 - 101, ISBN 978-0-470-03470-5, XP009559183 | - |
| OPPOSITION | - Royal College Of Physicians, "CHRONIC HEART FAILURE National clinical guideline for diagnosis and management in primary and secondary care", National clinical guideline for diagnosis and management in primary and secondary care (Full version of NICE Clinical Guideline No 108), Royal College Of Physicians, GB, GB, pages 1 - 646, National clinical guideline for diagnosis and management in primary and secondary care (Full version of NICE Clinical Guideline No 108), URL: https://www.ncbi.nlm.nih.gov/books/NBK65340/pdf/Bookshelf_NBK65340.pdf, XP093197874 | - |
| OPPOSITION | - University Of Ottawa Heart Institute, "Paradigm Heart Failure Presentation - Lisa M. Mielniczuk, MD", URL: https://www.youtube.com/watch?v=7CsnUwOGZS0, XP093299303 | - |
| OPPOSITION | - Wehling, Martin; Diener, Hans-Christoph; ; Manns, Michael P. , "2.2 Chronische Herzinsuffizienz", Klinische Pharmakologie: 256 Tabellen, Stuttgart, Georg Thieme Verlag, (20110101), pages 64 - 75, ISBN 978-3-13-126822-8, XP009559091 | - |
| OPPOSITION | - XP019601150 | - |
| OPPOSITION | - Z. Kobalava, Averkov O. , Meray I. , Alexandriya L. , Moiseev V. , Albrecht D. , Feng A. , Chandra P. , Jordaan P.J., "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: Effect on ANP, BNP, NT-proBNP and cGMP", European Heart Journal, (20110101), vol. 32, no. P4396, P4409, pages 784; - 785; 788, XP055751748 | - |
| OPPOSITION | - Daniel Levy, Martin G. Larson, Ramachandran S. Vasan, et al, "The Progression From Hypertension to Congestive Heart Failure", JAMA: Journal of the American Medical Association, American Medical Association, (19960522), vol. 275, no. 20, doi:10.1001/jama.1996.03530440037034, ISSN 0254-9077, pages 1557 - 1562, XP009562224 | |
| OPPOSITION | - Brandt Roland R, Scott Wright R, Redfield Margaret M, Burnett John C, "Atrial Natriuretic Peptide in Heart Failure", Atrial Natriuretic Peptide in Heart Failure, (19931001), vol. 22, no. 4, doi:10.1016/0735-1097(93)90468-g, pages 86A - 92A, XP093299297 | |
| OPPOSITION | - Gaggin Hanna K.; Januzzi James L., "Biomarkers and diagnostics in heart failure", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE., AMSTERDAM, NL, NL , (20130109), vol. 1832, no. 12, doi:10.1016/j.bbadis.2012.12.014, ISSN 0925-4439, pages 2442 - 2450, XP028768850 | |
| OPPOSITION | - Gustafsson, F. Steensgaard-Hansen, F. Badskjaer, J. Poulsen, A.H. Corell, P. Hildebrandt, P., "Diagnostic and Prognostic Performance of N-Terminal ProBNP in Primary Care Patients With Suspected Heart Failure", JOURNAL OF CARDIAL FAILURE., CHURCHILL LIVINGSTONE, NAPERVILLE, IL., US, US , (20050601), vol. 11, no. 5, doi:10.1016/j.cardfail.2005.04.022, ISSN 1071-9164, pages S15 - S20, XP004929813 | |
| OPPOSITION | - Thomas H. Langenickel, William P.Dole, "Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure", Drug Discovery Today: Therapeutic Strategies, doi:10.1016/j.ddstr.2013.11.002, (20120101), pages e131 - e139, Drug Discovery Today: Therapeutic Strategies, (20201118), XP055751770 | |
| OPPOSITION | - Maisel, A. ; Mueller, C. ; Adams, K. ; Anker, S.D. ; Aspromonte, N. ; Cleland, J.G.F. ; Cohen-Solal, A. ; Dahlstrom, U. ; DeMaria, A. ; Di Somma, S. ; Filippatos, G.S. ; Fonarow, G.C. ; Jourdain, P. ; Komajda, M. ; Liu, P.P. ; McDonagh, T. ; McDonald, K. ; Mebazaa, A. ; Nieminen, M.S. ; Peacock, W.F. ; Tubaro, M. ; Valle, R. ; Vanderhyden, M. ; Yancy, C.W. ; Zannad, F. ; Braunwald, E., "State of the art: Using natriuretic peptide levels in clinical practice", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL , (20080901), vol. 10, no. 9, doi:10.1016/j.ejheart.2008.07.014, ISSN 1388-9842, pages 824 - 839, XP025427959 | |
| OPPOSITION | - Val-HeFT Investigators ; Masson, S. ; Latini, R. ; Anand, I.S. ; Barlera, S. ; Angelici, L. ; Vago, T. ; Tognoni, G. ; Cohn, J.N., "Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial)", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20080916), vol. 52, no. 12, doi:10.1016/j.jacc.2008.04.069, ISSN 0735-1097, pages 997 - 1003, XP025405086 | |
| OPPOSITION | - Lainchbury John G.; Troughton Richard W.; Strangman Kim M.; Frampton Christopher M.; Pilbrow Anna; Yandle Timothy G.; Hamid Amjad K.; Nicholls M. Gary; Richards A. Mark, "N-Terminal Pro-B-Type Natriuretic Peptide-Guided Treatment for Chronic Heart Failure Results From the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) Trial", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (19000101), vol. 55, no. 1, doi:10.1016/j.jacc.2009.02.095, ISSN 0735-1097, pages 53 - 60, XP029647844 | |
| OPPOSITION | - CORONA Study Group ; Cleland, J.G.F. ; McMurray, J.J.V. ; Kjekshus, J. ; Cornel, J.H. ; Dunselman, P. ; Fonseca, C. ; Hjalmarson, A. ; Korewicki, J. ; Lindberg, M. ; Ranjith, N. ; van Veldhuisen, D.J. ; Waagstein, F. ; Wedel, H. ; Wikstrand, J., "Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20091110), vol. 54, no. 20, doi:10.1016/j.jacc.2009.06.041, ISSN 0735-1097, pages 1850 - 1859, XP026738328 | |
| OPPOSITION | - Yancy Clyde W.; Jessup Mariell; Bozkurt Biykem; Butler Javed; Casey Donald E.; Drazner Mark H.; Fonarow Gregg C.; Geraci Stephen A.; Horwich Tamara; Januzzi James L.; Johnson Maryl R.; Kasper Edward K.; Levy Wayne C.; Masoudi Frederick A.; McBride Patrick E.; McMurray John J.V.; Mitchell Judith E.; Peterson Pamela N.; Riegel Barbara; Sam Flora; Stevenson Lynne W.; Tang W.H. Wilson; Tsai Emily J.; Wilkoff Bruce L., "2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines ", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20130605), vol. 62, no. 16, doi:10.1016/j.jacc.2013.05.019, ISSN 0735-1097, XP028733857 | |
| OPPOSITION | - Doron Aronson; Henry Krum;, "Novel therapies in acute and chronic heart failure", Pharmacology & Therapeutics, ELSEVIER., GB, GB , (20120701), vol. 135, no. 1, doi:10.1016/j.pharmthera.2012.03.002, ISSN 0163-7258, pages 1 - 17, XP028503167 | |
| OPPOSITION | - He B. Julie, Anderson Mark E, "Aldosterone and cardiovascular disease: the heart of the matter", Trends in Endocrinology and Metabolism, Elsevier sience publishing , new york , NY, US, US , (20130101), vol. 24, no. 1, doi:10.1016/j.tem.2012.09.004, ISSN 1043-2760, pages 21 - 30, XP093299290 | |
| OPPOSITION | - Troughton, R.W. Frampton, C.M. Yandle, T.G. Espine, E.A. Nicholls, M.G. Richards, A.M., "Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20000401), vol. 355, no. 9210, doi:10.1016/S0140-6736(00)02060-2, pages 1126 - 1130, XP004814689 | |
| OPPOSITION | - Luis Miguel Ruilope, Andrej Dukat, Michael Böhm, Yves Lacourcière, Jianjian Gong, Martin P Lefkowitz,, "Blood-pressure reduction with LCZ696, a novel dueal-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20100410), vol. 375, no. 9722, doi:10.1016/S0140-6736(09)61966-8, pages 1255 - 1266, XP002676955 | |
| OPPOSITION | - Scott D Solomon, Michael Zile, Burkert Pieske, Adriaan Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong, Martin Lefkowitz, Milton Packer, John Jv Mcmurray, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial", The Lancet, ¬J.B. Flint|, (20121001), vol. 380, no. 9851, doi:10.1016/S0140-6736(12)61227-6, ISSN 01406736, pages 1387 - 1395, XP055083562 | |
| OPPOSITION | - Cleland John Gf, Clark Andrew L, "Heart failure—does it matter whether LVEF is reduced?", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20121001), vol. 380, no. 9851, doi:10.1016/S0140-6736(12)61349-X, ISSN 0140-6736, pages 1363 - 1365, XP093292898 | |
| OPPOSITION | - Khalil Mohammed E, Basher Abul W, Brown Edward J, Alhaddad Imad A, "A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20010601), vol. 37, no. 7, doi:10.1016/S0735-1097(01)01229-3, ISSN 0735-1097, pages 1757 - 1764, XP093197711 | |
| OPPOSITION | - Ferreira-Gonzalez, I. ; Alonso-Coello, P. ; Sola, I. ; Pacheco-Huergo, V. ; Domingo-Salvany, A. ; Alonso, J. ; Montori, V. ; Permanyer-Miralda, G., "Composite Endpoints in Clinical Trials", Revista Española de Cardiología (English Edition), ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20080101), vol. 61, no. 3, doi:10.1016/S1885-5857(08)60116-4, ISSN 1885-5857, pages 283 - 290, XP023783546 | |
| OPPOSITION | - Shearer F, Lang C C, Struthers A D, "Renin-Angiotensin-Aldosterone System Inhibitors in Heart Failure", Clinical Pharmacology and Therapeutics, Nature Publishing Group, US, US , (20131001), vol. 94, no. 4, doi:10.1038/clpt.2013.135, ISSN 0009-9236, pages 459 - 467, XP093198094 | |
| OPPOSITION | - O Vardeny, T Tacheny, S D Solomon, "First-in-Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure", Clinical Pharmacology and Therapeutics, Nature Publishing Group, US, US , (20131001), vol. 94, no. 4, doi:10.1038/clpt.2013.146, ISSN 0009-9236, pages 445 - 448, XP055224441 | |
| OPPOSITION | - Lang Chim C., Struthers Allan D., "Targeting the renin-angiotensin-aldosterone system in heart failure", Nature Reviews Cardiology, Nature Publishing Group, GB, GB , (20130301), vol. 10, no. 3, doi:10.1038/nrcardio.2012.196, ISSN 1759-5002, pages 125 - 134, XP093195090 | |
| OPPOSITION | - Guo Deng Fu, Sun Yu Lin, Hamet Pavel, Inagami Tadashi, "The angiotensin II type 1 receptor and receptor-associated proteins", Cell Research, Springer Singapore, Singapore, Singapore , (20010901), vol. 11, no. 3, doi:10.1038/sj.cr.7290083, ISSN 1001-0602, pages 165 - 180, XP093299291 | |
| OPPOSITION | - COHN J N, TOGNONI G, "A RANDOMIZED TRIAL OF THE ANGIOTENSIN-RECEPTOR BLOCKER VALSARTAN IN CHRONIC HEART FAILURE", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20011206), vol. 345, no. 23, doi:10.1056/NEJMoa010713, ISSN 1533-4406, pages 1667 - 1675, XP009033568 | |
| OPPOSITION | - John J.V. Mcmurray, Milton Packer, Akshay S. Desai, Jianjian Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor C. Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile, "Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure", New England Journal of Medicine, New England Journal of Medicine, (20140911), vol. 371, no. 11, doi:10.1056/NEJMoa1409077, ISSN 00284793, pages 993 - 1004, XP055175908 | |
| OPPOSITION | - J. J. V. Mcmurray, S. Adamopoulos, S. D. Anker, A. Auricchio, M. Bohm, K. Dickstein, V. Falk, G. Filippatos, C. Fonseca, M. A. Gomez-Sanchez, T. Jaarsma, L. Kober, G. Y. H. Lip, A. P. Maggioni, A. Parkhomenko, B. M. Pieske, B. A. Popescu, P. K. Ronnevik, F. H. Rutten, J. Schwitter, P. Seferovic, J. Stepinska, P. T. Trindade, A. A. Voors, F. Zannad, A. Zeiher, J. J. Bax, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, T. Mcdonagh, C. Moulin, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, A. Vahanian, S. Windecker, L. A. Bonet, P. Avraamides, H. A. Ben Lamin, M. Brignole, A. Coca, P. Cowburn, H. Dargie, P. Elliott, F. A. Flachskampf, G. F. Guida, S. Hardman, B. Iung, B. Merkely, C. Mueller, J. N. Nanas, O. W. Nielsen, S. Orn, J. T. Parissis, P. Ponikowski, "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC", European Heart Journal, No longer published by Elsevier, (20120702), vol. 33, no. 14, doi:10.1093/eurheartj/ehs104, ISSN 0195668X, pages 1787 - 1847, XP055140708 | |
| OPPOSITION | - Mangiafico Sarah, Costello-Boerrigter Lisa C., Andersen Ingrid A., Cataliotti Alessandro, Burnett John C., "Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics", European Heart Journal, Oxford University Press, GB, GB , (20130321), vol. 34, no. 12, doi:10.1093/eurheartj/ehs262, ISSN 0195-668X, pages 886 - 893, XP055957205 | |
| OPPOSITION | - Carlsen Christian Malchau, Bay Morten, Kirk Vibeke, Gøtze Jens Peter, Køber Lars, Nielsen Olav Wendelboe, "Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N‐terminal pro brain natriuretic peptide: a 10‐year analysis from the Copenhagen Hospital Heart Failure Study", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL , (20120301), vol. 14, no. 3, doi:10.1093/eurjhf/hfs003, ISSN 1388-9842, pages 240 - 247, XP093195095 | |
| OPPOSITION | - John J. V. Mcmurray, Milton Packer, Akshay S. Desai, Jim Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean Rouleau, Victor C. Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL , (20130901), vol. 15, no. 9, doi:10.1093/eurjhf/hft052, ISSN 1388-9842, pages 1062 - 1073, XP055161544 | |
| OPPOSITION | - Hegde Laxminarayan, Yu Cecile, Renner Travis, Thibodeaux Harold, Armstrong Scott, Park Timothy, Cheruvu Madhavi, Olsufka Rachael, Sandvik Erik, Lane Cassie, Budman Joe, Hill Craig, Klein Uwe, Hegde Sharath, "Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, RAVEN PRESS, NEW YORK, NY, US, US , (20110401), vol. 57, no. 4, doi:10.1097/FJC.0b013e318210fc7e, ISSN 0160-2446, pages 495 - 504, XP009561823 | |
| OPPOSITION | - Gaggin Hanna K., Truong Quynh A., Rehman Shafiq U., Mohammed Asim A., Bhardwaj Anju, Parks Kimberly A., Sullivan Dorothy A., Chen‐tournoux Annabel, Moore Stephanie A., Richards A. Mark, Troughton Richard W., Lainchbury John G., Weiner Rory B., Baggish Aaron L., Semigran Marc J., Januzzi James L., "Characterization and Prediction of Natriuretic Peptide "Nonresponse" During Heart Failure Management: Results From the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) Study", CONGESTIVE HEART FAILURE, CHF INC., GREENWICH, CT, US, US , (20130501), vol. 19, no. 3, doi:10.1111/chf.12016, ISSN 1527-5299, pages 135 - 142, XP093198086 | |
| OPPOSITION | - Doust Jenny A, Pietrzak Eva, Dobson Annette, Glasziou Paul, "How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review", BMJ, BMJ, (20050319), vol. 330, no. 7492, doi:10.1136/bmj.330.7492.625, ISSN 0959-8138, page 625, XP093198046 | |
| OPPOSITION | - Packer Milton, Califf Robert M., Konstam Marvin A., Krum Henry, Mcmurray John J., Rouleau Jean-Lucien, Swedberg Karl, "Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure : The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)", Circulation, American Heart Association, US, US , (20020820), vol. 106, no. 8, doi:10.1161/01.CIR.0000029801.86489.50, ISSN 0009-7322, pages 920 - 926, XP093195122 | |
| OPPOSITION | - Engeli Stefan, Negrel Raymond, Sharma Arya M., "Physiology and Pathophysiology of the Adipose Tissue Renin-Angiotensin System", Hypertension, Lippincott Williams & Wilkins, US, US , (20000601), vol. 35, no. 6, doi:10.1161/01.hyp.35.6.1270, ISSN 0194-911X, pages 1270 - 1277, XP093299286 | |
| OPPOSITION | - Yancy Clyde W., Jessup Mariell, Bozkurt Biykem, Butler Javed, Casey Donald E., Colvin Monica M., Drazner Mark H., Filippatos Gerasimos S, "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America", Circulation, American Heart Association, US, US , (20170808), vol. 136, no. 6, doi:10.1161/CIR.0000000000000509, ISSN 0009-7322, XP009512425 | |
| OPPOSITION | - Yancy Clyde W, Yancy Clyde W, Jessup Mariell, Bozkurt Biykem, Butler Javed, Casey, Drazner Mark H, Fonarow Gregg C, Geraci Stephen A, Horwich Tamara, Januzzi James L, Johnson Maryl R, Kasper Edward K, Levy Wayne C, Masoudi Frederick A, Mcbride Patrick E, Mcmurray John, Mitchell Judith E, Peterson Pamela N, Riegel Barbara, Sam Flora, Stevenson Lynne W, Tang W, Tsai Emily J, Wilkoff Bruce L, "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines", Circulation, American Heart Association, US, US , (20131015), vol. 62, no. 16, doi:10.1161/CIR.0b013e31829e8776, ISSN 0009-7322, pages e147 - e239, XP093180312 | |
| OPPOSITION | - Chun Soohun, Tu Jack V., Wijeysundera Harindra C., Austin Peter C., Wang Xuesong, Levy Daniel, Lee Douglas S., "Lifetime Analysis of Hospitalizations and Survival of Patients Newly Admitted With Heart Failure", Circulation. Heart Failure, Lippincott Williams & Wilkins, US, US , (20120701), vol. 5, no. 4, doi:10.1161/CIRCHEARTFAILURE.111.964791, ISSN 1941-3289, pages 414 - 421, XP093299258 | |
| OPPOSITION | - Von Lueder, Et Al, "Renin-Angiotensin Blockade Combined with Natriuretic Peptide System Augmentation", Circ. Heart Fail, (20130101), vol. 6, doi:10.1161/CIRCHEARTFAILURE.112.000289, pages 594 - 605, XP055780114 | |
| OPPOSITION | - Fanaroff Alexander C., Clare Robert, Pieper Karen S., Mahaffey Kenneth W., Melloni Chiara, Green Jennifer B., Alexander John H., Jones W. Schuyler, Harrison Robert W., Mehta Rajendra H., Povsic Thomas J., Moreira Humberto G., Al-Khatib Sana M., Roe Matthew T., Kong David F., Mathews Robin, Tricoci Pierluigi, Holman Rury R., Wallentin Lars, Held Claes, Califf Robert M., Alexander Karen P., Lopes Renato D., "Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials", Circulation, American Heart Association, US, US , (20190212), vol. 139, no. 7, doi:10.1161/CIRCULATIONAHA.118.037202, ISSN 0009-7322, pages 863 - 873, XP093195423 | |
| OPPOSITION | - Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel D F, Jeng A Y, Lin T H, Zheng W, Dole W P, "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).", Journal of clinical pharmacology, Wiley-Blackwell Publishing, Inc., US, US , (20100401), vol. 50, no. 4, doi:10.1177/0091270009343932, ISSN 1552-4604, pages 401 - 414, XP002718352 | |
| OPPOSITION | - Martin P Lefkowitz, "LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension", BMC PHARMACOLOGY, BIOMED CENTRAL, LONDON, GB, GB , (20110801), vol. 11, no. Suppl 1, doi:10.1186/1471-2210-11-S1-O3, ISSN 1471-2210, page O3, XP021104814 | |
| OPPOSITION | - Chrysant, Steven G., "LCZ-696: angiotensin AT, receptor antagonist/neprilysin inhibitor treatment of heart failure treatment of hypertension", Drugs of the Future, Prous Science, ES, ES , (20110301), vol. 36, no. 3, doi:10.1358/dof.2011.36.3.1588061, ISSN 0377-8282, pages 183 - 190, XP009173432 | |
| OPPOSITION | - Voors A A; Dorhout B; Van Der Meer P, "The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK , (20130101), vol. 22, no. 8, doi:10.1517/13543784.2013.797963, ISSN 1354-3784, pages 1041 - 1047, XP009173461 | |
| OPPOSITION | - Atlas Steven A., " The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition", The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition, (20071001), vol. 13, no. 8, doi:10.18553/jmcp.2007.13.s8-b.9, pages S9 - S20, XP093299289 | |
| OPPOSITION | - Röhrig Bernd, Prel Jean-Baptist Du, Wachtlin Daniel, Kwiecien Robert, Blettner Maria, "Sample Size Calculation in Clinical Trials", DEUTSCHES ARZTEBLATT INTERNATIONAL FEB 2013, (20100101), vol. 107, no. 31-32, doi:10.3238/arztebl.2010.0552, ISSN 1866-0452, pages 552 - 556, XP093125528 | |
| OPPOSITION | - Dahlöf Björn, "Valsartan and the renin-angiotensin-aldosterone system: Blood pressure control and beyond", JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, Sage Publications Ltd., GB, GB , (20000601), vol. 1, no. 2_suppl, doi:10.3317/JRAAS.2000.047, ISSN 1470-3203, pages 14 - 16, XP093299283 | |
| OTHER | - Mangiafico Sarah, Costello-Boerrigter Lisa C., Andersen Ingrid A., Cataliotti Alessandro, Burnett John C., "Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics", European Heart Journal, GB , (20130321), vol. 34, no. 12, doi:10.1093/eurheartj/ehs262, ISSN 0195-668X, pages 886 - 893, XP055957205 | |
| OTHER | - Sabe Marwa A, Jacob Miriam S, Taylor David O, "A new class of drugs for systolic heart failure: The PARADIGM-HF study", CLEVELAND CLINIC JOURNAL OF MEDICINE, (20151001), vol. 82, no. 10, doi:10.3949/ccjm.82a.14163, pages 693 - 701, XP093197153 | |
| SEARCH | - DORON ARONSON ET AL, "Novel therapies in acute and chronic heart failure", PHARMACOLOGY AND THERAPEUTICS, vol. 135, no. 1, doi:10.1016/J.PHARMTHERA.2012.03.002, ISSN 0163-7258, (20120323), pages 1 - 17, (20120323), XP028503167 [A] 1-14 * the whole document * | |
| SEARCH | - CHI HEEM WONG ET AL, "Estimation of clinical trial success rates and related parameters", BIOSTATISTICS, GB, (20190401), vol. 20, no. 2, doi:10.1093/biostatistics/kxx069, ISSN 1465-4644, pages 273 - 286, XP055604937 [T] * page 279; table 2 * * figure 1 * | |
| SEARCH | - JOHN J. V. MCMURRAY ET AL, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact", EUROPEAN JOURNAL OF HEART FAILURE, (20130504), vol. 15, no. 9, doi:10.1093/eurjhf/hft052, ISSN 1388-9842, pages 1062 - 1073, XP055161544 [A] 1-14 * the whole document * | |
| SEARCH | - VOORS A A ET AL, "The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, (20130101), vol. 22, no. 8, doi:10.1517/13543784.2013.797963, ISSN 1354-3784, pages 1041 - 1047, XP009173461 [A] 1-14 * the whole document * | |
